XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure        
Pay vs Performance Disclosure, Table
Value of Initial Fixed $100 Investment Based On: (4)
YearSummary Compensation Table (SCT) Total for PEOCompensation Actually Paid to PEO Average SCT Total for (Non-PEO) NEOsAverage Compensation Actually Paid to (Non-PEO) NEOs Total Shareholder ReturnPeer Group Total Shareholder Return
Net Loss
(Thousands)
Net Sales
(Thousands)
(1)(2)
(1)(3)
(1)(2)
(1)(3)
(5)(5)
2023$1,160,206$1,032,920$691,588$595,554$33.18$128.23$(4,938)$83,570
2022$1,158,850$843,376$721,425$546,641$38.98$127.63$(16,540)$72,050
2021$1,103,160$2,098,802$786,258$1,007,306$86.77$126.13$(27,128)$67,449
2020$1,126,685$1,311,277$719,114$815,729$111.37$113.29$(19,925)$59,257
      
Company Selected Measure Name Net Sales      
Named Executive Officers, Footnote NEOs included in these columns reflect the following individuals:
YearPEONon-PEO NEOs
2023Robert Fried Brianna Gerber
2022Robert FriedKevin Farr*, Frank Jaksch Jr.*, Brianna Gerber
2021Robert FriedKevin Farr, Frank Jaksch Jr., Lisa Harrington*
2020Robert FriedKevin Farr, Frank Jaksch Jr., Mark Friedman*, Megan Jordan*
*No longer serving as executive officer at the respective fiscal year-end.
     
Peer Group Issuers, Footnote The amounts shown compare the Company’s cumulative TSR with the Russell 3000 Pharmaceuticals and Biotechnology Sector (Sub-Index Ticker IQT689273826) cumulative TSR for the period beginning on the last trading day of fiscal year 2019 through the end of the applicable fiscal year. Pursuant to SEC rules, the comparison assumes that the value of the investment in the Company’s common shares and the Russell 3000 Pharmaceuticals and Biotechnology Sector was $100 and that all dividends were reinvested. The Company has not declared or paid any cash dividends on its common stock during any of the years presented.      
PEO Total Compensation Amount $ 1,160,206 $ 1,158,850 $ 1,103,160 $ 1,126,685
PEO Actually Paid Compensation Amount $ 1,032,920 843,376 2,098,802 1,311,277
Adjustment To PEO Compensation, Footnote CAP has been calculated based on the requirements and methodology set forth in the applicable SEC rules (Item 402(v) of Regulation S-K). The CAP calculation includes the end-of-year value of awards granted within the fiscal year, the change in fair value from prior year end of vested awards and the change in the fair value of unvested awards granted in prior years, regardless of if, when, or at which intrinsic value they will actually vest. To calculate CAP for fiscal year 2023 the following amounts were deducted from and added to the total compensation number shown in the SCT:
Reconciliation of Summary Compensation Table Total to Compensation Actually Paid
Fiscal Year 2023
(For PEO)
Fiscal Year 2023
(Average for Non-PEO NEOs)
Summary Compensation Table Total Compensation $1,160,206$691,588
Less: Grant Date Fair Value of Equity Awards Granted in the Fiscal Year
(391,249)(209,433)
Less: Change in Pension Value
——
Add: Fair Value at Fiscal Year End of Outstanding and Unvested Equity Awards Granted in the Fiscal Year
284,706152,401
Adjust for: Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Fiscal Years
(21,902)(30,410)
Adjust for: Fair Value at Vesting of Equity Awards Granted and Vested in the Fiscal Year
——
Adjust for: Change in Fair Value as of Vesting Date of Equity Awards Granted in Prior Fiscal Years that Vested in the Fiscal Year
1,159(8,592)
Less: Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year
——
Add: Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation
——
Compensation Actually Paid$1,032,920$595,554

For purposes of the above adjustments, the fair value of equity awards on the applicable date were determined in accordance with FASB’s ASC Topic 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes.

The table below contains ranges of assumptions used in the valuation of outstanding equity awards for the relevant fiscal year(s). For more information, see Note 11 of the ChromaDex Corporation consolidated financial statements included in the Annual Report on Form 10-K.
Fiscal Year 2023
Restricted Stock Units
Stock Price
$1.43 - $1.68
Stock Options
Expected Term (years)
5.0 - 8.7
Strike Price
$1.69 - $11.83
Volatility
72.3% - 77.6%
Dividend Yield
0%
Risk-Free Interest Rate
3.3% - 4.7%
      
Non-PEO NEO Average Total Compensation Amount $ 691,588 721,425 786,258 719,114
Non-PEO NEO Average Compensation Actually Paid Amount $ 595,554 546,641 1,007,306 815,729
Adjustment to Non-PEO NEO Compensation Footnote CAP has been calculated based on the requirements and methodology set forth in the applicable SEC rules (Item 402(v) of Regulation S-K). The CAP calculation includes the end-of-year value of awards granted within the fiscal year, the change in fair value from prior year end of vested awards and the change in the fair value of unvested awards granted in prior years, regardless of if, when, or at which intrinsic value they will actually vest. To calculate CAP for fiscal year 2023 the following amounts were deducted from and added to the total compensation number shown in the SCT:
Reconciliation of Summary Compensation Table Total to Compensation Actually Paid
Fiscal Year 2023
(For PEO)
Fiscal Year 2023
(Average for Non-PEO NEOs)
Summary Compensation Table Total Compensation $1,160,206$691,588
Less: Grant Date Fair Value of Equity Awards Granted in the Fiscal Year
(391,249)(209,433)
Less: Change in Pension Value
——
Add: Fair Value at Fiscal Year End of Outstanding and Unvested Equity Awards Granted in the Fiscal Year
284,706152,401
Adjust for: Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Fiscal Years
(21,902)(30,410)
Adjust for: Fair Value at Vesting of Equity Awards Granted and Vested in the Fiscal Year
——
Adjust for: Change in Fair Value as of Vesting Date of Equity Awards Granted in Prior Fiscal Years that Vested in the Fiscal Year
1,159(8,592)
Less: Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year
——
Add: Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation
——
Compensation Actually Paid$1,032,920$595,554

For purposes of the above adjustments, the fair value of equity awards on the applicable date were determined in accordance with FASB’s ASC Topic 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes.

The table below contains ranges of assumptions used in the valuation of outstanding equity awards for the relevant fiscal year(s). For more information, see Note 11 of the ChromaDex Corporation consolidated financial statements included in the Annual Report on Form 10-K.
Fiscal Year 2023
Restricted Stock Units
Stock Price
$1.43 - $1.68
Stock Options
Expected Term (years)
5.0 - 8.7
Strike Price
$1.69 - $11.83
Volatility
72.3% - 77.6%
Dividend Yield
0%
Risk-Free Interest Rate
3.3% - 4.7%
      
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid Versus Total Shareholder Return

The following chart illustrates the relationship between CAP for our PEO and the average CAP for our Non-PEO NEOs against the Company’s TSR, as well as the relationship between our TSR and the TSR of our peer group, the Russell 3000 Pharmaceuticals and Biotechnology Sector:

4732
      
Compensation Actually Paid vs. Net Income
Compensation Actually Paid Versus Net Income

The following chart illustrates the relationship between CAP for our PEO and the average CAP for our Non-PEO NEOs against the Company’s net income:

4781
      
Compensation Actually Paid vs. Company Selected Measure
Compensation Actually Paid Versus Net Sales

The following chart illustrates the relationship between CAP for our PEO and the average CAP for our Non-PEO NEOs against the Company’s net sales:

4829
      
Total Shareholder Return Vs Peer Group
Compensation Actually Paid Versus Total Shareholder Return

The following chart illustrates the relationship between CAP for our PEO and the average CAP for our Non-PEO NEOs against the Company’s TSR, as well as the relationship between our TSR and the TSR of our peer group, the Russell 3000 Pharmaceuticals and Biotechnology Sector:

4732
      
Tabular List, Table
Tabular List
Net Sales
Operating Income / (Loss)
     
Total Shareholder Return Amount $ 33.18 38.98 86.77 111.37
Peer Group Total Shareholder Return Amount 128.23 127.63 126.13 113.29
Net Income (Loss) $ (4,938,000) $ (16,540,000) $ (27,128,000) $ (19,925,000)
Company Selected Measure Amount 83,570,000 72,050,000 67,449,000 59,257,000
PEO Name Robert Fried Robert Fried Robert Fried Robert Fried
Additional 402(v) Disclosure Reflects the total compensation paid to our PEO and the average total compensation of our non-PEO NEOs as calculated in the Summary Compensation Table (SCT) for each year shown.Net Loss and Net Sales shown as reported in our audited financial statements for each year. In the Company's assessment, Net Sales is the financial performance measure that is the most important financial performance measure (other than total shareholder return and net income) used by the company in fiscal year 2023 to link compensation actually paid to performance.      
Equity Valuation Assumption, Stock Price, RSU, Minimum $ 1.43      
Equity Valuation Assumption, Stock Price, RSU, Maximum $ 1.68      
Equity Valuation Assumption, Expected Term, Options, Minimum 5 years      
Equity Valuation Assumption, Expected Term, Options, Maximum 8 years 8 months 12 days      
Equity Valuation Assumption, Strike Price, Options, Minimum $ 1.69      
Equity Valuation Assumption, Strike Price, Options, Maximum $ 11.83      
Equity Valuation Assumption, Volatility, Options, Minimum 72.30%      
Equity Valuation Assumption, Volatility, Options, Maximum 77.60%      
Equity Valuation Assumption, Dividend Yield, Options 0.00%      
Equity Valuation Assumption, Risk Free Interest Rate, Options, Minimum 3.30%      
Equity Valuation Assumption, Risk Free Interest Rate, Options, Maximum 4.70%      
Measure:: 1        
Pay vs Performance Disclosure        
Name Net Sales      
Measure:: 2        
Pay vs Performance Disclosure        
Name Operating Income / (Loss)      
PEO | Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 0      
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (391,249)      
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 284,706      
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (21,902)      
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,159      
PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
Non-PEO NEO | Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (209,433)      
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 152,401      
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (30,410)      
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (8,592)      
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 0